Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALVOPAD PS: AVT02 versus Humira in Moderate-to-Severe Chronic Plaque Psoriasis
2017-003367-35Phase 3Completed
- Sponsor
- Alvotech
- Start
- Nov 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of AVT02 in psoriasis (2 arms), sponsored by Alvotech. Started Nov 2018; status: completed.
02
Drugs
AVT02
03
Conditions
psoriasis
Beyond the preview
Go deeper on 2017-003367-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003367-35.